Table 1.
Disease characteristics of the 16 patients with head and neck cancers included in this study.
| P# | Cancer Site | T | N | M | Stage | P | V | E | Margin | Diff |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Rt Hypopharynx | 1 | 2b | 0 | 4a | n | n | n | involved | poor |
| 2 | Lt Tongue Base | 2 | 1 | 0 | 3 | n | Y | n | involved | mod |
| 3 | FOM | 4 | 0 | 0 | 4a | Y | n | x | x | poor |
| 4 | RT Supraglottis | 2 | 2b | 0 | 4a | n | n | Y | clear | poor |
| 5 | Rt Tongue Base | 1 | 2b | 0 | 4a | n | n | Y | involved | mod |
| 6 | Rt Tongue Base | 2 | 1 | 0 | 3 | n | Y | n | clear | mod |
| 7 | Lt Hypopharynx | 4 | 2c | 0 | 4a | n | n | Y | 5 mm | poor |
| 8 | Glottic | 4 | 0 | 0 | 4a | x | n | x | clear | mod |
| 9 | Rt Lat Tongue | 1 | 0 | 0 | 1 | Y | n | x | 10 mm | well |
| 10 | Lt Tonsil | 3 | 2b | 0 | 4a | n | n | Y | involved | poor |
| 11 | Rt Tonsil | 2 | 2b | 0 | 4a | n | n | Y | clear | mod |
| 12 | Glottic | 3 | 0 | 0 | 3 | x | n | x | 15 mm | mod |
| 13 | Glottic | 3 | 0 | 0 | 3 | n | n | x | 0 mm | mod |
| 14 | Transglottic | 4 | 0 | 0 | 4a | x | Y | x | 1 mm | Mod |
| 15 | Rt Lat Tongue | 3 | 1 | 0 | 3 | n | n | Y | 3 mm | poor |
| 16 | Rt Lat Tongue | 3 | 0 | 0 | 3 | n | n | x | 0.6 mm | well |
| P# | Recurrence | Radiation | Chemo | Outcome | Before | After | ||||
| 1 | Distant | Y - 66 Gy in 32 | n | Alive - metastatic disease | neg | POS | ||||
| 2 | Local (tonsil) | Y - 64 Gy in 31 | n | Died - disease | POS | neg | ||||
| 3 | Local (tongue) | Y - 64 Gy in 32 | n | Died - disease | POS | neg | ||||
| 4 | Local (Node) | Y - 66 Gy in 32 | n | Died - disease | POS | neg | ||||
| 5 | Local | Y - 66 Gy in 33 | n | Died - metastatic disease | POS | neg | ||||
| 6 | n | n | n | Alive - Disease Free | POS | POS | ||||
| 7 | Distant | Y - 66 Gy in 32 | n | died - metastatic disease | POS | POS | ||||
| 8 | n | Y - 66 Gy in 33 | n | Alive - Disease Free | POS | POS | ||||
| 9 | Distant | Y - 66 Gy in 34 | n | died - metastatic disease | POS | POS | ||||
| 10 | Distant | Y - 66 Gy in 35 | Y | died - metastatic disease | neg | POS | ||||
| 11 | n | Y - 66 Gy in 36 | Y | Alive - Disease Free | POS | POS | ||||
| 12 | n | n | n | died - other | neg | neg | ||||
| 13 | Local | Y - 64 Gy in 31 | Y | Alive - Disease Free | POS | POS | ||||
| 14 | Local | Y - 64 Gy in 31 | n | died - metastatic disease | neg | neg | ||||
| 15 | Local | n | n | died - metastatic disease | POS | POS | ||||
| 16 | n | n | n | Alive - Disease Free | neg | POS | ||||
P# denotes patient number. Information includes - Site of original cancer (cancer site); tumour size (T); nodal status (N); evidence of metastasis (M); evidence of perineural invasion (P); evidence of vascular invasion (V); evidence of extracapsular invasion (E); whether the margin was involved with tumour after surgery or clear; differentiation of the tumour (Diff); Site of recurrence (Recurrence); whether (Y), or not (n), radiation was given post-surgery (Radiation) including dosage - Grays (Gy) in fractions; whether (Y), or not (n), chemotherapy was given (Chemo); the outcome at last follow-up (Outcome); and whether the patients were positive (POS) or negative (neg), before and after surgery for at least 2 of the RT-PCR markers. Y denotes yes, n denotes no, x denotes unknown.